4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Randomized controlled trial assessing the effectiveness of midazolam premedication as an anxiolytic, analgesic, sedative, and hemodynamic stabilizer

      research-article
      , MD a , b , , MD, PhD a , b , , , MD a , , MD, PhD a , , MD, PhD a , , MD, PhD a , , MD a
      Medicine
      Wolters Kluwer Health
      anesthesia adjuvants, midazolam, premedication

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Midazolam premedication is widely used before general anesthesia, but lacks clinical evidence of effectiveness. The present study aimed to evaluate the effectiveness of midazolam premedication following 4 aspects: anxiety reduction, sedation, hemodynamic stabilization, and analgesia.

          Methods:

          In a randomized, single-blind, prospective study, a total of 128 women were allocated to the midazolam premedication group (Group P, n = 64) or the control group (Group N, n = 64). The patients were asked to complete the Beck anxiety inventory (BAI) 2 times: on the day before surgery (BS) and 30 minutes after midazolam premedication (T0). Depth of anesthesia using state entropy (SE), conventional hemodynamic data using heart rate (HR) and mean blood pressure (MBP), and analgesic profiles using surgical pleth index (SPI) were acquired at the following 4 points: T1—pre-induction, T2—prior to intubation, T3—intubation, and T4—20 minutes after intubation.

          Results:

          No change in BAI score was observed between BS and T0 in both groups P and N (median and interquartile range [IQR], Group P: BS—4.5 [2.0–7.0], T0—4.0 [1.0–9.0], P = .603; Group N: BS—4.0 [1.0–8.5], T0—3.5 [1.0–6.0], P = .066). Midazolam premedication reduced SE at T2–4 (mean difference with 95% confidence interval [95% CI], T2—7.1 [1.6–12.6], P = .012; T3—10.4 [6.5–14.4], P < .001; T4—9.2 [5.0–13.4], P < .001). Midazolam premedication also reduced HR (mean differences [95% CI], T1—7.3 [2.5–12.1], P = .003; T3—6.6 [1.1–12.2], P = .020) and MBP at T1 and T3 (mean differences [95% CI], T1—7.3 [2.5–12.1], P = .003; T3—8.6 [1.3–15.9], P = .021), and lowered SPI at T1–3 (mean differences [95% CI]: T1—12.7 [6.1–19.4], P < .001; T2—6.0 [0.5–11.5], P = .033; T3—7.9 [1.7–14.1], P = .012).

          Conclusion:

          Midazolam premedication did not reduce the level of anxiety. However, midazolam premedication reduced the entropy values, stabilized hemodynamics, and provided analgesia during the induction of anesthesia. The purpose of midazolam premedication needs to be reconsidered.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: not found
          • Article: not found

          Autonomic nervous system activity in emotion: A review

          Autonomic nervous system (ANS) activity is viewed as a major component of the emotion response in many recent theories of emotion. Positions on the degree of specificity of ANS activation in emotion, however, greatly diverge, ranging from undifferentiated arousal, over acknowledgment of strong response idiosyncrasies, to highly specific predictions of autonomic response patterns for certain emotions. A review of 134 publications that report experimental investigations of emotional effects on peripheral physiological responding in healthy individuals suggests considerable ANS response specificity in emotion when considering subtypes of distinct emotions. The importance of sound terminology of investigated affective states as well as of choice of physiological measures in assessing ANS reactivity is discussed. Copyright © 2010 Elsevier B.V. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Benzodiazepine pharmacology and central nervous system-mediated effects.

            Owing to the low therapeutic index of barbiturates, benzodiazepines (BZDs) became popular in this country and worldwide many decades ago for a wide range of conditions. Because of an increased understanding of pharmacology and physiology, the mechanisms of action of many BZDs are now largely understood, and BZDs of varying potency and duration of action have been developed and marketed. Although BZDs have many therapeutic roles and BZD-mediated effects are typically well tolerated in the general population, side effects and toxicity can result in morbidity and mortality for some patients. The elderly; certain subpopulations of patients with lung, liver, or kidney dysfunction; and patients on other classes of medication are especially prone to toxicity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.

              Benzodiazepines (BZDs) remain important agents in the management of epilepsy. They are drugs of first choice for status epilepticus and seizures associated with post-anoxic insult and are also frequently used in the treatment of febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in a variety of clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. Potential shortcomings of BZDs include tolerance, withdrawal symptoms, adverse events, such as cognitive impairment and sedation, and drug interactions. Benzodiazepines differ in their pharmacologic effects and pharmacokinetic profiles, which dictate how the drugs are used. Among the approximately 35 BZDs available, a select few are used for the management of seizures and epilepsy: clobazam, clonazepam, clorazepate, diazepam, lorazepam and midazolam. Among these BZDs, clorazepate has a unique profile that includes a long half-life of its active metabolite and slow onset of tolerance. Additionally, the pharmacokinetic characteristics of clorazepate (particularly the sustained-release formulation) could theoretically help minimize adverse events. However, larger, controlled studies of clorazepate are needed to further examine its role in the treatment of patients with epilepsy.
                Bookmark

                Author and article information

                Journal
                Medicine (Baltimore)
                Medicine (Baltimore)
                MEDI
                Medicine
                Wolters Kluwer Health
                0025-7974
                1536-5964
                August 2018
                21 August 2018
                : 97
                : 35
                : e12187
                Affiliations
                [a ]Department of Anesthesia and Pain Medicine
                [b ]Medical Research Institute, Pusan National University Hospital, School of Medicine, Busan, Republic of Korea.
                Author notes
                []Correspondence: Hyeon-Jeong Lee, Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea (e-mail: lhjksk@ 123456pusan.ac.kr ).
                Article
                MD-D-18-04079 12187
                10.1097/MD.0000000000012187
                6393069
                30170468
                a1fc7a34-3b34-424f-a34b-fed1957be575
                Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

                This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

                History
                : 9 June 2018
                : 9 August 2018
                Categories
                3300
                Research Article
                Clinical Trial/Experimental Study
                Custom metadata
                TRUE

                anesthesia adjuvants,midazolam,premedication
                anesthesia adjuvants, midazolam, premedication

                Comments

                Comment on this article